Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Merck
Dow
Moodys
Mallinckrodt
Baxter
Medtronic

Last Updated: November 22, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,716,867

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,716,867 protect, and when does it expire?

Patent 6,716,867 protects PRECEDEX and is included in one NDA.

Protection for PRECEDEX has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-nine patent family members in twenty-eight countries.

Summary for Patent: 6,716,867
Title: Use of dexmedetomidine for ICU sedation
Abstract:The present invention relates to a method of sedating a patient while in the intensive care unit comprising administering dexmedetomidine of a pharmaceutically acceptable salt thereof to the patient, wherein the patient remains arousable and orientated.
Inventor(s): Aantaa; Riku (Turku, FI), Bachand; Romeo (Mundelain, IL), Heinonen; Esa (Turku, FI)
Assignee: Orion Corporation (Espoo, FI)
Application Number:09/647,364
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,716,867
Patent Claim Types:
see list of patent claims
Use; Composition; Delivery;

Drugs Protected by US Patent 6,716,867

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Hospira PRECEDEX dexmedetomidine hydrochloride INJECTABLE;INJECTION 021038-004 Nov 14, 2014 AP RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Hospira PRECEDEX dexmedetomidine hydrochloride INJECTABLE;INJECTION 021038-001 Dec 17, 1999 AP RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Hospira PRECEDEX dexmedetomidine hydrochloride INJECTABLE;INJECTION 021038-002 Mar 13, 2013 AP RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Hospira PRECEDEX dexmedetomidine hydrochloride INJECTABLE;INJECTION 021038-003 Mar 13, 2013 AP RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 6,716,867

PCT Information
PCT FiledMarch 31, 1999PCT Application Number:PCT/FI99/00266
PCT Publication Date:October 07, 1999PCT Publication Number: WO99/49854

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
McKesson
Baxter
Colorcon
Merck
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.